- Advertise
- Contact Us
- Editorial Info
- Contribute
- Terms and Conditions
- Privacy Policy
- Do not sell my Personal Information
© 2022 MJH Life Sciences™ and Rheumatology Network. All rights reserved.
Ankylosing Spondylitis
Désirée van der Heijde, MD, PhD: Safety, Efficacy of Bimekizumab in Ankylosing Spondyloarthritis
June 14, 2022
Désirée van der Heijde, MD, PhD, explains the results of a recent trial evaluating the safety and efficacy of bimekizumab in patients with active ankylosing spondylitis.
Filip Van den Bosch, MD: Safety and Efficacy of Upadacitinib for nr-axSpA
June 03, 2022
Filip Van den Bosch, MD, discusses his presentation, “Efficacy and Safety of Upadacitinib in Patients With Active Non-Radiographic Axial Spondyloarthritis: a Double-Blind, Randomized, Placebo-Controlled Phase 3 Trial."
Upadacitinib Achieves Promising Results for Axial Spondyloarthritis Treatment
June 03, 2022
Upadacitinib met the primary endpoint of ASAS40 in patients with active non-radiographic axial spondyloarthritis and treatment-refractory active ankylosing spondylitis with inadequate response to biologic disease-modifying antirheumatic drugs.
Poor Exercise Adherence Reported in Patients with Ankylosing Spondylitis
May 11, 2022
Of 185 outpatients that completed the questionnaire, 146 patients (78.9%) were considered to have poor adherence to exercise therapy.
Increased Risk of Aortic Regurgitation, Atrial Fibrillation in Patients With Radiographic Axial Spondyloarthritis
May 04, 2022
The European Alliance of Associations for Rheumatology (EULAR) recommends screening and early management of cardiovascular disease in patients with radiographic axial spondyloarthritis.
Secukinumab Improves Disease Activity in Patients With PsA, axSpA
April 25, 2022
A notable percentage of patients with rheumatic diseases, such as psoriatic arthritis, stop taking bDMARDs due to lack of effectiveness and adverse events.
Q&A: IL-18 Serum Levels and Cardiovascular Risk in Psoriatic Arthritis, Ankylosing Spondylitis
March 07, 2022
In this Q&A, Krzysztof Bonek, MD, PhD, discussed the findings of his study that looked at the associations of IL-18 serum levels with serum lipids, cardiovascular risk and disease activity in patients with ankylosing spondylitis and psoriatic arthritis.
Bimekizumab Meets Primary and Secondary Endpoints for Treating Axial Spondyloarthritis
January 18, 2022
Bimekizumab, an interleukin 17A (IL-17A) and IL-17F inhibitor, met both primary and secondary endpoints for treating adult patients with non-radiographic axial spondyloarthritis.
Fatigue and Pain Levels Remain High in Patients With Ankylosing Spondylitis
December 02, 2021
“Managing pain is an important treatment goal in patients with ankylosing spondylitis, however, pain is often underestimated by clinical disease activity scoring tools, and 20% to 30% of patients report pain despite treatment with TNFis,” investigators stated.
Upadacitinib Meets Primary and Most Ranked Secondary Endpoints in 2 Phase 3 Clinical Trials
October 08, 2021
Upadacitinib achieved positive results from both Phase 3 SELECT-AXIS clinical trials, which focused on patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis.